Mario Bigioni

2.3k total citations
58 papers, 1.8k citations indexed

About

Mario Bigioni is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Mario Bigioni has authored 58 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 17 papers in Oncology and 8 papers in Organic Chemistry. Recurrent topics in Mario Bigioni's work include Cancer therapeutics and mechanisms (19 papers), Histone Deacetylase Inhibitors Research (7 papers) and Protein Degradation and Inhibitors (6 papers). Mario Bigioni is often cited by papers focused on Cancer therapeutics and mechanisms (19 papers), Histone Deacetylase Inhibitors Research (7 papers) and Protein Degradation and Inhibitors (6 papers). Mario Bigioni collaborates with scholars based in Italy, United States and Spain. Mario Bigioni's co-authors include Carlo Alberto Maggi, Antonino De Lorenzo, Laura Di Renzo, Monica Binaschi, M G Premrov, Cristina Goso, Stefano Manzini, Giovanni Capranico, V. Del Gobbo and Fabio Galvano and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and American Journal of Clinical Nutrition.

In The Last Decade

Mario Bigioni

57 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mario Bigioni Italy 25 796 376 301 294 259 58 1.8k
Xiaoping Yang China 22 895 1.1× 317 0.8× 159 0.5× 749 2.5× 193 0.7× 53 2.2k
Erwin Bischoff Germany 24 826 1.0× 143 0.4× 224 0.7× 159 0.5× 221 0.9× 49 2.0k
Pei Yu China 32 962 1.2× 190 0.5× 182 0.6× 98 0.3× 255 1.0× 116 2.5k
Albert Breier Slovakia 27 1.4k 1.8× 869 2.3× 167 0.6× 129 0.4× 158 0.6× 140 2.4k
Michaela Adamcová Czechia 30 543 0.7× 478 1.3× 181 0.6× 1.6k 5.5× 128 0.5× 98 2.7k
Rebecca A. Lew Australia 26 1.2k 1.5× 513 1.4× 179 0.6× 1.0k 3.5× 251 1.0× 70 3.1k
Aspandiar G. Katki United States 20 1.1k 1.3× 598 1.6× 95 0.3× 78 0.3× 157 0.6× 27 2.0k
Chong Zhang China 26 1.2k 1.6× 376 1.0× 123 0.4× 95 0.3× 268 1.0× 128 2.6k
Yuko Tsuda Japan 25 957 1.2× 249 0.7× 350 1.2× 66 0.2× 194 0.7× 166 2.1k
Chi‐Chung Chan Canada 25 1.0k 1.3× 135 0.4× 377 1.3× 113 0.4× 709 2.7× 41 2.7k

Countries citing papers authored by Mario Bigioni

Since Specialization
Citations

This map shows the geographic impact of Mario Bigioni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Bigioni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Bigioni more than expected).

Fields of papers citing papers by Mario Bigioni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mario Bigioni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Bigioni. The network helps show where Mario Bigioni may publish in the future.

Co-authorship network of co-authors of Mario Bigioni

This figure shows the co-authorship network connecting the top 25 collaborators of Mario Bigioni. A scholar is included among the top collaborators of Mario Bigioni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mario Bigioni. Mario Bigioni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zicari, Sonia, Giuseppe Merlino, Alessio Fiascarelli, et al.. (2024). The Dual PIM/FLT3 Inhibitor MEN1703 Combines Synergistically With Gilteritinib in FLT3‐ITD‐Mutant Acute Myeloid Leukaemia. Journal of Cellular and Molecular Medicine. 28(23). e70235–e70235. 1 indexed citations
2.
Merlino, Giuseppe, Alessio Fiascarelli, Patrizia Tunici, et al.. (2023). Abstract 2849: The oral SERD Elacestrant in combination with the PI3K inhibitor MEN1611 inhibits tumor growth in ER+/HER2- breast cancer in vitro and in PDX models. Cancer Research. 83(7_Supplement). 2849–2849. 1 indexed citations
3.
Fiascarelli, Alessio, Giuseppe Merlino, Alessandro Bressan, et al.. (2023). Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer. Breast Cancer Research and Treatment. 199(1). 13–23. 5 indexed citations
4.
Merlino, G., Mario Bigioni, Patrizia Tunici, et al.. (2021). 489P MEN1611 in combination with cetuximab: Targeting PIK3CA mutations in RAS-wild-type patient-derived colorectal cancer xenografts. Annals of Oncology. 32. S573–S573. 2 indexed citations
5.
Bressan, A., Mario Bigioni, Maurizio Scaltriti, et al.. (2019). Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models. Annals of Oncology. 30. v781–v782. 7 indexed citations
6.
Cipollone, Amalia, Marielle Paris, Marina Porcelloni, et al.. (2013). Benzofused hydroxamic acids: Useful fragments for the preparation of histone deacetylase inhibitors. Part 1: Hit identification. Bioorganic & Medicinal Chemistry Letters. 23(14). 4091–4095. 7 indexed citations
7.
Bigioni, Mario, Patrizia Felicetti, Cristina Rossi, et al.. (2012). Set-up of a new series of HDAC inhibitors: the 5,11-dihydrodibenzo[b,e]azepin-6-ones as privileged structures. Bioorganic & Medicinal Chemistry Letters. 22(17). 5360–5362. 11 indexed citations
8.
Binaschi, Monica, Cecilia Simonelli, Cristina Goso, Mario Bigioni, & Carlo Alberto Maggi. (2011). Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach. Experimental and Therapeutic Medicine. 2(2). 173–180. 5 indexed citations
9.
Rossi, Cristina, Marina Porcelloni, Mario Bigioni, et al.. (2011). 4-N-Hydroxy-4-[1-(sulfonyl)piperidin-4-yl]-butyramides as HDAC inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(22). 6767–6769. 6 indexed citations
10.
Binaschi, Monica, Maurizio Gianni’, Carlo Alberto Maggi, et al.. (2010). Antiproliferative and Differentiating Activities of a Novel Series of Histone Deacetylase Inhibitors. ACS Medicinal Chemistry Letters. 1(8). 411–415. 74 indexed citations
11.
Renzo, Laura Di, et al.. (2010). α-Lipoic Acid Supplementation: A Tool for Obesity Therapy?. Current Pharmaceutical Design. 16(7). 840–846. 59 indexed citations
12.
Bigioni, Mario, Carlo Alberto Maggi, Stefano Manzini, et al.. (2007). Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft. Cancer Chemotherapy and Pharmacology. 62(4). 621–629. 19 indexed citations
13.
Lorenzo, Antonino De, V. Del Gobbo, M G Premrov, et al.. (2007). Normal-weight obese syndrome: early inflammation?. American Journal of Clinical Nutrition. 85(1). 40–45. 201 indexed citations
14.
Animati, Fabio, Mario Bigioni, Monica Binaschi, et al.. (2007). Synthesis, Biological Evaluation, and Molecular Modeling Studies of Rebeccamycin Analogues Modified in the Carbohydrate Moiety. ChemMedChem. 3(2). 266–279. 17 indexed citations
15.
Renzo, Laura Di, et al.. (2006). Normal Weight Obese syndrome: role of single nucleotide polymorphism of IL-1 5Ralpha and MTHFR 677C-->T genes in the relationship between body composition and resting metabolic rate.. PubMed. 10(5). 235–45. 43 indexed citations
16.
Palma, Carla, et al.. (2000). Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. British Journal of Cancer. 82(2). 480–487. 64 indexed citations
17.
Arcamone, Federico, Fabio Animati, Mario Bigioni, et al.. (1999). Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides. Biochemical Pharmacology. 57(10). 1133–1139. 25 indexed citations
18.
Pourquier, Philippe, Stella Tinelli, Monica Binaschi, et al.. (1999). Topoisomerase Poisoning Activity of Novel Disaccharide Anthracyclines. Molecular Pharmacology. 56(1). 77–84. 54 indexed citations
19.
Arcamone, F, Fabio Animati, Mario Bigioni, et al.. (1997). Doxorubicin Disaccharide Analogue: Apoptosis-Related Improvement of Efficacy In Vivo. JNCI Journal of the National Cancer Institute. 89(16). 1217–1223. 54 indexed citations
20.
Bigioni, Mario, Franco Zunino, & Giovanni Capranico. (1994). Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage. Nucleic Acids Research. 22(12). 2274–2281. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaoping Yang Breakdown of academic impact, for papers by Erwin Bischoff Breakdown of academic impact, for papers by Pei Yu Breakdown of academic impact, for papers by Albert Breier Breakdown of academic impact, for papers by Michaela Adamcová Breakdown of academic impact, for papers by Rebecca A. Lew Breakdown of academic impact, for papers by Aspandiar G. Katki Breakdown of academic impact, for papers by Chong Zhang Breakdown of academic impact, for papers by Yuko Tsuda Breakdown of academic impact, for papers by Chi‐Chung Chan
Rankless by CCL
2026